Junshi Biosciences Reports Results of VV116 (JT001) in the P-III Registrational Trial for Early Treatment of COVID-19 in High Risk Patients
Shots:
- The P-III study evaluates VV116 (JT001) vs Paxlovid in 822 patients with COVID-19 who are at high risk for progression to sev. COVID-19 including death
- The trial met its pre-specified 1EPs & 2EPs i.e., the therapy exhibited a shorter time to sustained clinical recovery and was statistically superior, no COVID-19 disease progression or death were observed along with time to sustained disappearance of clinical symptoms & the time to patient testing negative for SARS-CoV-2 & has a good safety profile, the overall incidence of AE was lower than Paxlovid
- In the P-I trials, VV116 exhibited good safety, tolerability & PK in healthy patients. VV116 is an oral nucleoside analogue therapy that can stop SARS-CoV-2 from replicating
Ref: Globenewswire | Image: Junshi Biosciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
